Charles River Laboratories International
Open
$164.44
Prev. Close
$164.64
High
$164.57
Low
$164.31
Market Snapshot
$8.06B
-55.9
0.21
$4.05B
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
emptyResult
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Recently from Cashu
Charles River Laboratories' Adaptation Strategies Amid Evolving Drug Development Challenges
Charles River Laboratories and the Evolving Landscape of Drug Development Charles River Laboratories International, a key player in the biotechnology sector, finds itself in a context where drug devel…
Charles River Laboratories Enhances Focus Through Strategic Business Divestiture for Growth
Charles River Laboratories Transitions Focus Through Strategic Divestiture Charles River Laboratories International takes a decisive step toward enhancing operational efficiency by announcing its inte…
Charles River Laboratories Restructures to Enhance Focus on Core Biotechnology Competencies
Charles River Laboratories Restructures for Enhanced Focus on Core Competencies Charles River Laboratories International, a key player in the biotechnology and pharmaceutical sectors, announces a stra…
Analysts Tighten Focus on Charles River Laboratories' Strategy and Operational Execution
Analyst Spotlight Tightens on Charles River’s Strategic Direction Debate Over Charles River’s Growth Model and Operational Priorities Over the past three months eight analysts scrutinize Charles River…